Skip to content
Docosanol
Abreva (docosanol) is a small molecule pharmaceutical. Docosanol was first approved as Abreva on 2000-07-25. It is used to treat blister in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Abreva (generic drugs available since 2018-11-19)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Docosanol
Tradename
Company
Number
Date
Products
ABREVAGSKN-020941 OTC2000-07-25
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
abrevaANDA2022-03-15
docosanolANDA2023-03-29
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
blister—D001768—
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D06: Antibiotics and chemotherapeutics for dermatological use
— D06B: Chemotherapeutics for topical use
— D06BB: Antivirals, topical
— D06BB11: Docosanol
HCPCS
No data
Clinical
Clinical Trials
2 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atrial fibrillationD001281EFO_0000275I48.0——1—12
Cardiovascular diseasesD002318EFO_0000319I98——1——1
Heart diseasesD006331EFO_0003777I51.9——1——1
Cardiac arrhythmiasD001145EFO_0004269I49.9——1——1
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDOCOSANOL
INN—
Description
Docosan-1-ol is a long-chain primary fatty alcohol that is docosane substituted by a hydroxy group at position 1. It has a role as an antiviral agent. It is a long-chain primary fatty alcohol and a fatty alcohol 22:0. It derives from a hydride of a docosane.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCCCCCCCCCCCCCCCCCCCCO
Identifiers
PDB—
CAS-ID661-19-8
RxCUI594680
ChEMBL IDCHEMBL1200453
ChEBI ID31000
PubChem CID12620
DrugBankDB00632
UNII ID—
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 353 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
804 adverse events reported
View more details